A
study on ferrets showed the product dubbed INNA-051, which could
be used complementary to vaccines, lowered the levels of the
virus that causes COVID-19 by up to 96%, the company said. The
study was led by British government agency Public Health
England.
Ena Respiratory said it would be ready to test INNA-051 in human
trials in less than four months, subject to successful toxicity
studies and regulatory approval.
The company has raised A$11.7 million ($8.24 million) for the
development of the spray. Investors include venture capital firm
Brandon Capital Ltd, the Australian federal government, pension
funds and biotech giant CSL Ltd <CSL.AX>.
Several companies across the world are in the pursuit of
developing a coronavirus vaccine. Australia has entered into
agreements with some drug companies investing billions to secure
potential vaccines for COVID-19, which has killed over 992,000
people worldwide.
Australia has so far reported 875 deaths and just over 27,000
coronavirus cases, far less than the numbers reported in other
developed countries.
(Reporting by Renju Jose; Editing by Ana Nicolaci da Costa)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.

|
|